Syremis Therapeutics Overview
- Year Founded
-
2025
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$165M
- Investors
-
6
Syremis Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop novel medicines that address major unmet needs in mental health care. The company offers a neuropsychiatric drug pipeline rooted in emerging and clinically validated biology, such as muscarinic M1/M4 agonism and next-generation NMDA antagonism, enabling customers to access more effective and better-tolerated treatments for conditions like schizophrenia, major depressive disorder and bipolar depression, ultimately reducing disability, relapse rates and improving quality of life.
Contact Information
Website
www.syremis.comCorporate Office
- Tel Aviv
- Israel
Corporate Office
- Tel Aviv
- Israel
Syremis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 02-Dec-2025 | $165M | Completed | Pre-Clinical Trials |
Syremis Therapeutics Patents
Syremis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026202849-A1 | Pharmaceutically acceptable salts of n-acetyl-d-valine dextrorphan | Pending | 28-Mar-2025 | ||
| WO-2026126144-A1 | Xanomeline combinations for treating neurological disorders | Pending | 12-Dec-2024 | ||
| WO-2026018155-A1 | Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists | Pending | 16-Jul-2024 | ||
| WO-2026018154-A1 | Combinations of sabcomeline with non-cns penetrant muscarinic antagonists | Pending | 16-Jul-2024 | ||
| US-20260102381-A1 | Muscarinic agent combinations | Pending | 16-Jul-2024 | A61K31/439 |
Syremis Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Dexcel Pharma | Corporation | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| Pictet | Asset Manager | Minority | ||
| QVT Family Office | Family Office | Minority |
Syremis Therapeutics FAQs
-
When was Syremis Therapeutics founded?
Syremis Therapeutics was founded in 2025.
-
Where is Syremis Therapeutics headquartered?
Syremis Therapeutics is headquartered in Tel Aviv, Israel.
-
What industry is Syremis Therapeutics in?
Syremis Therapeutics’s primary industry is Biotechnology.
-
Is Syremis Therapeutics a private or public company?
Syremis Therapeutics is a Private company.
-
What is Syremis Therapeutics’s current revenue?
The current revenue for Syremis Therapeutics is .
-
How much funding has Syremis Therapeutics raised over time?
Syremis Therapeutics has raised $165M.
-
Who are Syremis Therapeutics’s investors?
Bain Capital Life Sciences, Dexcel Pharma, GV, Pictet, and QVT Family Office are 5 of 6 investors who have invested in Syremis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process